Glembatumumab vedotin

Ott et al; ESMO 2016 Poster, October 2016
"A Phase 2 Study of Glembatumumab Vedotin (GV), an Antibody-Drug Conjugate (ADC) Targeting gpNMB, in Advanced Melanoma"
PDF Read More →

Halim et al; AACR 2016 Poster, April 2016
"Glycoprotein NMB (gpNMB) Overexpression is Prevalent in Human Cancers: Pancreatic Cancer, Non-Small Cell Lung Cancer, Head and Neck Cancer, and Osteosarcoma"
PDF Read More →

Yardley et al; ASCO Breast Cancer Symposium 2015 Poster, September 2015
“gpNMB Expression Patterns in Breast Cancer (BC): Retrospective Evaluation of Tumor Tissue from the Phase 2 EMERGE Study”
PDF Read More →

Yardley et al; ASCO 2015 Poster, May 2015
“METRIC: A Randomized International Study of the Antibody-Drug Conjugate Glembatumumab Vedotin (GV or CDX-011) in Patients (pts) with Metastatic gpNMB-Overexpressing Triple-Negative Breast Cancer (TNBC)”
PDF Read More →

Yardley et al; Journal of Clinical Oncology, May 2015
"EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer"
Read More →

Yardley et al; SABCS 2013 Poster, December 2013
“A Pivotal, Multicenter, Randomized Study Evaluating the Novel Antibody-drug Conjugate Glembatumumab Vedotin (CDX-011; CR011-vcMMAE) in Patients with Metastatic, Triple-negative, gpNMB Over-expressing Breast Cancer”
PDF Read More →

Yardley et al; SABCS 2012 Poster, December 2012
“A Randomized Phase II Study of the Antibody-drug Conjugate CDX-011 in Advanced GPNMB Overexpressing Breast Cancer: The EMERGE Study”
PDF Read More →

Hamid et al; ASCO 2010 Poster, June 2010
“Frequent Dosing and GPNMB Expression with CDX-011 (CRO11-vcMMAE), an Antibody-Drug Conjugate (ADC), in Patients with Advanced Melanoma”
PDF Read More →

Saleh et al; ASCO 2010 Poster, June 2010
“Correlation of GPNMB Expression with Outcome in Breast Cancer (BC) Patients Treated with the Antibody-Drug Conjugate (ADC), CDX-011 (CR011-vcMMAE)
PDF Read More →

Rose at al; Clinical Cancer Research, April 2010
“Glycoprotein Nonmetastatic B Is an Independent Prognostic Indicator of Recurrence and a Novel Therapeutic Target in Breast Cancer”
Read More →

Burris et al; SABCS 2009 Poster, December 2009
“A Phase I/II Study of CR011-vcMMAE (CDX-011), an Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Breast Cancer”
PDF Read More →

Peacock et al; ASCO 2009 Poster, June 2009
“A Phase I/II Study of CR011-vcMMAE, an Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Breast Cancer”
PDF Read More →

Hwu et al; ASCO 2009 Poster, June 2009
“A Phase I/II Study of CR011-vcMMAE, an Antibody-Drug Conjugate Targeting GPNMB in Patients with Advanced Melanoma”
PDF Read More →

Pollack et al; Cancer Chemotherapy and Pharmacology, March 2007
“Treatment parameters modulating regression of human melanoma xenografts by an antibody–drug conjugate  (CR011-vcMMAE) targeting GPNMB”
Read More →

Tse at al; Clinical Cancer Research, February 2006
“CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma”
Read More →


Varlilumab

Sanborn et al; AACR 2016 Poster; April 2016
"Phase 1 results from the combination of an immune-activating anti-CD27 antibody (varlilumab) in combination with PD-1 blockade (nivolumab): activation across multiple immune pathways without untoward immune-related adverse events"
PDF Read more → 

He et al; SITC 2015 Poster; November 2015
"The mechanism of anti-tumor immunity induced by varlilumab, a CD27 agonist mAb, is model dependent"
PDF Read more → 

Ramakrishna et al; Journal for ImmunoTherapy of Cancer; August 2015
"Characterization of the human T cell response to in vitro CD27 costimulation with varlilumab"
PDF Read more → PDF Supplemental data →

Thomas et al; AACR 2015 Poster; April 2015
"Synergistic anti-tumor activity of PD-1 signaling blockade and CD27 costimulation correlates with enhanced ratio of effector to regulatory T cells at the tumor site "
PDF Read more →

Bullock et al; SITC 2014 Poster, November 2014
“Immune Correlates of Varlilumab (CDX-1127) Treated Cancer Patients are Consistent with CD27 Costimulatory Activity”
PDF Read More →

Infante et al; ASCO 2014 Poster, June 2014
“Immunological Activity of an Activating Anti-CD27 Antibody (Varlilumab [CDX-1127]) in Patients with Solid Tumors”
PDF Read More →

Ansell et al; ASCO 2014 Poster, June 2014
“Phase I Evaluation of an Agonist Anti-CD27 Human Antibody (Varlilumab [CDX-1127]) in Patients with Advanced Hematologic Malignancies”
PDF Read More →

Thomas et al; OncoImmunology, January 2014
“Targeting human CD27 with an agonist antibody stimulates T cell activation and antitumor immunity”
PDF Read More →

Keler et al; SITC 2013 Poster, November 2013
“Combination Therapies Augment the Anti-Tumor Activity of Agonist CD27 mAb in Human CD27 Transgenic Mouse Models”
PDF Read More →

Burris, et al; SITC 2013 Poster, November 2013
“A Phase I Study of an Agonist Anti-CD27 Human Antibody (CDX-1127) in Patients with Advanced Hematologic Malignancies or Solid Tumors”
PDF Read More →

Ansell, Stephen; SITC 2013 Poster, November 2013
“A Phase I Study of an Agonist Anti-CD27 Human Antibody (CDX-1127) in Patients with Advanced Hematologic Malignancies or Solid Tumors”
PDF Read More →

He et al; Journal of Immunology, September 2013
“Agonist Anti-Human CD27 Monoclonal Antibody Induces T Cell Activation and Tumor Immunity in Human CD27 Transgenic Mice
PDF Read More →

Sundarapandiyan et al; AACR 2013 Poster, April 2013
“Characterization of the Response of Human T cells to an Agonistic Anti-CD27 mAb”
PDF Read More →

Vitale et al; Clinical Cancer Research, May 2012
“Development of a Human Monoclonal Antibody for Potential Therapy of CD27-Expressing Lymphoma and Leukemia”
Read More →

He et al; AACR 2012 Poster, April 2012
“Appropriate cross-linking is required for co-stimulatory activity of human anti-CD27 antibody in a transgenic mouse model”
PDF Read More →

He et al; ASH 2011 Poster, December 2011
“Development of a Human Anti-CD27 Antibody with Efficacy in Lymphoma and Leukemia Models by Two Distinct Mechanisms”
PDF Read More →

Thomas et al; AACR 2011 Poster, April 2011
“Anti-tumor Activity of a Fully Human anti-CD27 Monoclonal Antibody in a Transgenic Mouse Model”
PDF Read More →

He et al; AACR 2010 Poster, April 2010
“Development of Novel Anti-CD27 Human Antibodies with Therapeutic Potential”
PDF Read More →


CDX-1401

Bhardwaj et al; ASCO 2016 Poster, June 2016
"A Phase 2, Open-label, Multicenter, Randomized Study of CDX-1401, a Dendritic Cell Targeting NY-ESO-1 Vaccine, in Patients with Malignant Melanoma Pre-Treated with CDX-301, a Recombinant Human Flt3 Ligand"
PDF Read More →

Halim et al; AACR 2016 Poster, April 2016
"IHC and RT-PCR Assays for Detection of Cancer Antigen NY-ESO-1 in Human Tissues"
PDF Read More →

Dhodapkar et al; Science Translational Medicine, April 2014 
“Induction of Antigen-Specific Immunity with a Vaccine Targeting NY-ESO-1 to the Dendritic Cell Receptor DEC-205”
 Read More →

Dhodapkar et al; SITC 2012 Poster, October 2012
“A Phase 1 Trial of a Novel Vaccine Targeting NY-ESO-1 to the Dendritic Cell Receptor DEC-205 in Combination with Toll-like Receptor Agonists”
PDF Read More →

Tsuji et al; The Journal of Immunology, January 2011
“Antibody-Targeted NY-ESO-1 to Mannose Receptor or DEC-205 In Vitro Elicits Dual Human CD8+ and CD4+ T Cell Responses with Broad Antigen Specificity”
Read More →

Dhodapkar et al; iSBTc 2010 Poster, October 2010
“Early Development of CDX-1401, A Novel Vaccine Targeting NY-ESO-1 to the Dendritic Cell Receptor DEC-205, in Combination with Toll-like Receptor Agonists”
PDF Read More →


CDX-301

Marron et al; AACR 2016 Poster, April 2016
"In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy"
PDF Read More →

Jaglowski et al; ASBMT 2016 Poster, February 2016
"Preliminary Safety and Efficacy Data using CDX-301 (Flt3 ligand) as a Sole Agent to Mobilize Hematopoietic Cells Prior to HLA-matched Sibling Donor Transplantation"
PDF Read More →

Anandasabapathy et al; Bone Marrow Transplantation, April 2015
“Efficacy and safety of CDX-301, recombinant human Flt3L, at expanding dendritic cells and hematopoietic stem cells in healthy human volunteers”
Read More →

Yellin et al; BMT 2013 Presentation, February 2013
“A Phase 1 Trial of the Hematopoietic Growth Factor CDX-301 (rhuFlt3L) in Healthy Volunteers”  
PDF Read More →

Anandasabapathy et al; ASH 2012 Poster, December 2012
“A Phase 1 Trial of the Hematopoietic Growth Factor CDX-301 (rhuFlt3L) in Healthy Volunteers”
PDF Read More →


CDX-014

Thomas et al; Molecular Cancer Therapeutics, September 2016
“Development of a Novel Antibody-drug Conjugate for the Potential Treatment of Ovarian, Lung and Renal Cell Carcinoma Expressing TIM-1”
Read More →

Thomas et al; AACR 2014 Poster, April 2014
“Development of an Antibody-drug Conjugate Targeting TIM-1 for the Treatment of Ovarian and Renal Cell Carcinoma”  
PDF Read More →


CDX-1140

Vitale et al; SITC 2016 Poster, November 2016
“Functional characterization of CDX-1140, a novel CD40 antibody agonist for cancer immunotherapy”
PDF Read More →

Vitale et al; AACR 2016 Poster, April 2016
“Development and characterization of novel CD40 antibody agonists for cancer immunotherapy”
PDF Read More →


RINTEGA® (rindopepimut)

In March 2016, Celldex announced that based on the recommendation of the Data Safety and Monitoring Board for the Company’s Phase 3 study of RINTEGA in newly diagnosed glioblastoma that the study would be discontinued as it was unlikely to meet its primary overall survival endpoint in patients with minimal residual disease.
Read the Press Release →

Weller et al; SNO 2016 Presentation, November 2016
"ACT IV: An international, double-blind, phase 3 trial of rindopepimut in newly diagnosed, EGFRvIII-expressing glioblastoma"
PDFRead More →

Reardon and Sampson et al; SNO 2015 Presentation, November 2015
"ReACT: Long-term survival from a randomized phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma"
PDFRead More →

Reardon and Sampson et al; ASCO 2015 Presentation, May 2015
"ReACT: Overall survival from a randomized phase II study of rindopepimut (CDX-110) plus bevacizumabin relapsed glioblastoma"
PDF Read More →

Schuster and Lai et al; Neuro-Oncology, January 2015
“A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study.”
PDF Read More →

Reardon et al; SNO 2014 Presentation, November 2014
“ReACT: A Phase II Study of Rindopepimut Vaccine (CDX-110) Plus Bevacizumab in Relapsed Glioblastoma(GBM)”
PDF Read More →

Reardon et al; SNO 2013 Presentation, November 2013
“ReACT: A Phase II Study of Rindopepimut Vaccine (CDX-110) Plus Bevacizumab in Relapsed Glioblastoma (GBM)"
PDF Read More →

SNO 2012 Data, November 2012
“Celldex Therapeutics Announces Positive Three-Year Survival Data for Rindopepimut Phase 2 Clinical Program”
Read More →

Adamson and Babu et al; Core Evidence, September 2012
“Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-positive glioblastoma”
PDF Read More →

Lai et al; SNO 2011 Presentation, November 2011
“Long-term Follow-up of ACT III: A Phase II Trial of Rindopepimut”
PDF Read More →

Sampson et al; Journal of Neuro-Oncology, December 2010
“Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma”
Read More →

Lai et al; SNO 2010 Poster, November 2010
“Final Analysis of PFR in ACT III: A Phase II Trial of Rindopepimut (CDX-110) with Temozolomide in Patients with Newly Diagnosed GBM”
PDF Read More →

Sampson et al; Journal of Clinical Oncology, November 2010
“Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients with Newly Diagnosed Glioblastoma”
Read More →

Lai et al; ASCO 2010 Presentation, June 2010
“Interim Data for ACT III—Phase II Trial of Rindopepimut (PF-04948568, CDX-110) in Combination with Temozolomide (TMZ) in Patients with Glioblastoma (GBM)”
PDF Read More →

Lai et al; ASCO 2010 Poster, June 2010
“Interim Data for ACT III—Phase II Trial of Rindopepimut (PF-04948568, CDX-110) in Combination with Temozolomide (TMZ) in Patients with Glioblastoma (GBM)”
PDF Read More →

This list contains core publications from each of our development programs, but it is not comprehensive. If you would like to take a deeper dive in any of our programs, please contact us.